|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CHI3L1 is a susceptibility gene for asthma, bronchial hyperresponsiveness, and reduced lung function, and elevated circulating YKL-40 levels are a biomarker for asthma and decline in lung function.
|
18403759 |
2008 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
CHI3L1 is a susceptibility gene for asthma, bronchial hyperresponsiveness, and reduced lung function, and elevated circulating YKL-40 levels are a biomarker for asthma and decline in lung function.
|
18403759 |
2008 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
YKL-40, also known as chitinase-like protein, has been shown to be related to various inflammatory conditions including atherosclerosis, diabetes, cancer, and asthma.
|
29028081 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CHI3L1 is a secreted glycoprotein and associated with inflammation, fibrosis, asthma, extracellular tissue remodeling and solid tumors.
|
30121622 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chitinase 3-like 1 protein (CHI3L1) (YKL-40 in humans and breast regression protein [BRP]-39 in mice) is required for optimal allergen sensitization and Th2 inflammation in various chronic inflammatory diseases including asthma.
|
30402955 |
2019 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A highly significant relation between serum levels of periostin and YKL40 and asthma severity, p value for each was <0.001.
|
29970479 |
2018 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After stratified according to ethnicity, CHI3L1 rs4950928 variant was associated with decreased asthma risk in Caucasians (GG + GC vs. CC: OR = 0.621, 95% CI = 0.484-0.797, P = 0.000; GC vs. CC: OR = 0.612, 95% CI = 0.470-0.796, P = 0.000; G vs. C: OR = 0.696, 95% CI = 0.567-0.856, P = 0.001).
|
29233108 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although YKL-40 is expressed in exaggerated quantities and correlates with disease activity in asthma and many other disorders, the biological properties of BRP-39/YKL-40 have only been rudimentarily defined.
|
19414556 |
2009 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Completion of the human genome sequence and the advent of genome-wide association studies have resulted in the identification of two novel asthma susceptibility genes, ORMDL3 and CHI3L1, in the past year.
|
18769193 |
2008 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Following adjustment for CHI3L1 genotype, significantly greater levels of YKL-40 were found in children with therapy-resistant asthma than in children with controlled asthma.
|
23628340 |
2013 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, a significant correlation with the genotypes in CHI3L1/YKL-40 was observed in the context of stress and asthma severity.
|
23190377 |
2013 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast to the promoter SNP rs4950928, the intronic SNP rs12141494 in CHI3L1 is associated with asthma severity, lung function, and YKL-40 expression in the blood and airway.
|
25592985 |
2015 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the Tsukuba GWAS cohort, the C allele at rs946261 was significantly associated with reduced expression of CHI3L1 mRNA in the lung and with development of asthma (odds ratio (OR) 1.27; P = 0.036).
|
30940096 |
2019 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, it has been reported that rs10399931 (-329 G/A) of CHI3LI contributes to the inter-individual plasma YKL-40 levels in patients with sarcoidosis, and that rs4950928 (-131 C/G) is a susceptibility polymorphism for asthma and a decline in lung function.
|
19421404 |
2009 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has never been addressed whether SNPs in CHI3L1 and cord blood YKL-40 levels could already serve as potential biomarkers for milder forms of asthma.
|
27193312 |
2016 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Less is known about non-type 2 inflammation but blood neutrophils and YKL-40 may be higher in patients with evidence of non-type 2 asthma.
|
31652141 |
2020 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the CHI3L1 polymorphisms rs1538372 and rs10399931 can be used as genetic markers for predicting asthma risk in the Taiwanese population.
|
25056157 |
2014 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that CCL18 and YKL-40 levels and CHIT1 activity are enhanced in allergic airway inflammation and thus may contribute to airway remodelling in asthma.
|
23331560 |
2013 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasma YKL-40 levels were examined in relation to CHI3L1 rs4950928 genotype and clinical characteristics including Asthma Predictive Index, medication use, time spent with respiratory symptoms, atopic status, and blood leukocytes.
|
27732738 |
2017 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma YKL-40 levels were significantly elevated in patients with asthma compared to those in control subjects (<i>p</i> < .05).
|
31295039 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
rDer p 1 significantly up-regulated the expression of PLA2G4A, PLA2G6, PLA2G15, CYSLTR1, LB4R2, PTGS1, PTGS2, FOXP1, GATA3, HDAC2, IREB2, PPARG, STAT4, TSLP and CHI3L1 genes in asthmatics in comparison to healthy subjects.
|
25634111 |
2014 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum YKL-40 may be used as a protein marker in classifying asthma severity by applying SPR technology as a reliable, label-free, highly sensitive, and cost-effective tool.
|
27616735 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum chitotriosidase and YKL-40 were significantly elevated in patients with asthma and those with COPD compared with healthy control subjects.
|
26372680 |
2016 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum periostin was high in both asthma and ACO, but not in COPD, whereas serum YKL-40 was high in both COPD and ACO, but not in asthma.
|
29981861 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The YKL-40 clusters are potentially useful for identification of individuals with severe or exacerbation-prone asthma.
|
29025889 |
2017 |